



SOM Biotech announces the presentation of the Phase2b study results in Huntington Chorea Patients at the HDG Conference in Cincinnati

Barcelona, Spain, October 15 2024. SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, announces the presentation of the top-line results of a Phase2b study with SOM3355 compound on Huntington patients with chorea at the Annual Meeting of the Huntington Study Group (HDG) in Cincinnati, Ohio, on November 7th-9th, 2024 at the session “Contemporary Trials and Next Steps”.

Silvia Panigone, PhD, MBA recently appointed as the new SOM Chief Executive Officer says “We are excited to share the results of the Phase2b study that tested two different doses of SOM3355 in patient with Chorea associated with Huntington disease. It has been a long journey for the company and we are proud to have achieved this important milestone”.

“We believe that the future of the treatment of Chorea associated with Huntington disease will be driven by the use of drugs that are most effective by combining improvement of chorea and no significant negative impact on depression, suicidal ideation and cognitive function, thus allowing long-term continued treatment without additional limitation of the daily living,” says Rossella Medori, M.D. the new Chief Medical Officer at SOM biotech.

“At this year’s HSG congress, we will present data from a just completed phase 2b clinical trials with SOM3355, our lead asset. This drug was identified by SOM AI platform and selected to be re-purposed in this indication thanks to a well-established safety profile and the new mechanism-of-action and will be a significant addition as a novel treatment approach for HD chorea.” For more information on the Phase2b study, please visit clinicaltrials.org.

SOM Board and leadership has been recently strengthened with the addition of industry veterans in the Board and highly experienced people in the management team to position the company for the next level growth.

About SOM Biotech: SOM Biotech (www.sombiotech.com) is a Spanish Headquartered biopharmaceutical company founded in 2009. It is based on a unique proprietary artificial intelligence (AI) platform (*SOM^{AI}PRO*) to identify new Mechanism of Actions of small molecules drugs for the treatment of diseases with high unmet medical need with a focus on orphan disorders in the CNS space. SOM has established a pipeline of products developed for the treatment of orphan indications among which TTR Amyloidosis, Huntington's disease and

Tardive Dyskinesia, and Phenylketonuria. TTR Amyloidosis product was licensed out upon positive Phase 2a data.

For more information about SOM Biotech, please contact:

info@sombiotech.com